GSK Beheer

Beheer criteriumcontroles 2/4

De CEO GSK is Emma Walmsley, benoemd in Apr2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 12.72M, bestaande uit 10.3% salaris en 89.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.04% van de aandelen van het bedrijf, ter waarde € 26.29M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6 jaar en 3.2 jaar.

Belangrijke informatie

Emma Walmsley

Algemeen directeur

UK£12.7m

Totale compensatie

Percentage CEO-salaris	10.3%
Dienstverband CEO	7.6yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Emma Walmsley's beloning veranderd ten opzichte van GSK's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	UK£3b
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Compensatie versus markt: De totale vergoeding ($USD 15.94M ) Emma } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.78M ).

Compensatie versus inkomsten: De beloning van Emma is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Emma Walmsley (55 yo)

7.6yrs

Tenure

UK£12,718,000

Compensatie

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Emma Walmsley	CEO & Director	7.6yrs	UK£12.72m	0.040% € 26.3m
Julie Brown	CFO & Executive Director	1.6yrs	UK£5.14m	0.0024% € 1.6m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.8yrs	geen gegevens	geen gegevens
Tony Wood	Chief Scientific Officer and Head of R&D	2.3yrs	geen gegevens	geen gegevens
Sarah Elton-Farr	Head of Investor Relations	no data	geen gegevens	geen gegevens
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.3yrs	geen gegevens	geen gegevens
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.7yrs	geen gegevens	geen gegevens
David Redfern	President of Corporate Development	no data	geen gegevens	geen gegevens
Diana Conrad	Chief People Officer	5.6yrs	geen gegevens	geen gegevens
Philip Thomson	President of Global Affairs	7.6yrs	geen gegevens	0.0057% € 3.8m
Luke Miels	Chief Commercial Officer	7.2yrs	geen gegevens	geen gegevens
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6.4yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GS71 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Emma Walmsley	CEO & Director	7.8yrs	UK£12.72m	0.040% € 26.3m
Julie Brown	CFO & Executive Director	1.5yrs	UK£5.14m	0.0024% € 1.6m
Jonathan Symonds	Non-Executive Chairman	5.2yrs	UK£765.00k	0.0020% € 1.3m
Vishal Sikka	Independent Non-Executive Director	2.3yrs	UK£147.00k	0.00036% € 237.2k
Hal Barron	Non-Executive Director	6.8yrs	UK£356.92k	0.032% € 21.2m
Harry Dietz	Independent Non-Executive Director	2.8yrs	UK£207.09k	0.00016% € 105.4k
Anne Beal	Independent Non-Executive Director	3.5yrs	UK£174.93k	0.00017% € 112.0k
Wendy Mira Becker	Independent Non-Executive Director	1.1yrs	UK£32.00k	0.000040% € 26.4k
Charles Bancroft	Senior Independent Non-Executive Director	4.5yrs	UK£323.00k	0.0014% € 942.3k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	geen gegevens	0.000030% € 19.8k
Elizabeth Anderson	Independent Non-Executive Director	2.2yrs	UK£127.86k	0.000090% € 59.3k
Jesse Goodman	Independent Non-Executive Director	8.8yrs	UK£173.36k	0.00073% € 481.0k

3.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GS71 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

GSK Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Gsk plc Announces Board Committee Changes

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

Recent updates

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

Third quarter 2024 earnings released: UK£0.014 loss per share (vs UK£0.36 profit in 3Q 2023)

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings released: EPS: UK£0.29 (vs UK£0.40 in 2Q 2023)

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings released: EPS: UK£0.26 (vs UK£0.37 in 1Q 2023)

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: UK£1.22 (vs UK£1.11 in FY 2022)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd